Breaking News: The FDA approved Eli Lilly’s drug, tirzepatide, for the treatment of obesity! The name for this drug is Zepbound™ and it is, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound, like all other AOMs, is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight/ preobesity (with a BMI of 27 kg/m2 or greater) and also have weight-related complications.
In this episode, Karli reviews the news release and discusses things like, when Zepbound is expected to be available, pricing, and the studies that lead to its FDA appoval.
News Release
Surmount 3
The Gaining Health Podcast will release a new episode monthly, every second Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.
If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer monthly and annual Memberships, which include live group coaching, a community forum to ask questions and post resources, pre-recorded Master Classes, digital resources inlcuding patient education materials and office forms, and much more!
We also sell our popular Gaining Health products, including a book on developing an obesity management program, editable forms and templates, and patient education materials in our Gaining Health Shop!
If you are loving this podcast, please consider supporting us on Patreon